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ABSTRACT
Patients with chronic lymphocytic leukemia (CLL) are
at a significantly increased risk of developing cutane-
ous squamous cell carcinoma (SCC), in part because
of their impaired immunosurveillance. Here, we re-
port the cases of 4 patients with CLL who had locally
aggressive cutaneous SCC managed with radiotherapy
for local recurrence following surgical excision. All
tumours were located in the head-and-neck region. All
patients initially achieved complete regression of dis-
ease; however, 2 had local recurrence a mean of 8
months after treatment completion. One patient died
from progressive SCC. Our findings agree with the high
rates reported in literature of multiple tumours, local
recurrence, metastases, and mortality from SCC in pa-
tients with CLL. Radiotherapy plays an important role
in patient management, and it is the recommended
treatment modality when complete surgical excision
of disease would result in anatomic and functional de-
fects. Radiotherapy is often used in the case of local
recurrence after one or more attempts at surgical ex-
cision. Dose escalation through intensity-modulated
radiotherapy, hyperfractionation, or novel treatment
techniques such as high-intensity focused ultrasound
may be explored to improve local control of SCC le-
sions. To optimize patient outcomes, cutaneous SCC
arising in patients with a history of CLL should be man-
aged and followed in a multidisciplinary clinic, with
regular skin surveillance and prompt treatment.
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1. INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most com-
mon adult leukemia in the United States and Western
Europe 1. Chronic lymphocytic leukemia is a clonal
disorder characterized by an increased number of ma-
ture B lymphocytes with prolonged survival. This
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incurable disease can have either an indolent or an ag-
gressive course; median survival is 7 years (range: a
few months to several decades). Death is typically the
result of infection or secondary malignancy 2,3.
Patients with CLL are at an increased risk of de-
veloping secondary malignancies, including cutaneous
squamous cell carcinoma (SCC) 4–6. The increased in-
cidence of cutaneous SCC is thought to be a result of
the impaired immunosurveillance seen in CLL patients,
together with a lack of repair of accumulated damage
from ultraviolet radiation on sun-exposed skin. In im-
munocompetent patients, high rates of local control and
cure of cutaneous SCC are achieved through electro-
desiccation and curettage, surgical excision, or local
radiotherapy 7. However, in patients with CLL, high
rates of multiple tumours, local recurrence, metastases,
and mortality from cutaneous SCC are seen 8–13.
Several reports in the literature have described the
role of surgical excision, including Mohs micrographic
surgery, in the treatment of cutaneous SCC in CLL pa-
tients 12,13. However, the role of radiotherapy has not
been previously described. Given the high rate of local
recurrence after primary surgery, the multifocal na-
ture of the disease, and the rapid rate of tumour growth,
radiotherapy plays an important role in the manage-
ment of cutaneous SCC in this patient population. Here,
we report on 4 patients with CLL and locally aggres-
sive cutaneous SCC that were managed at our center
with radiotherapy after local recurrence following sur-
gical excision.
2. CASE SELECTION
The multidisciplinary non-melanoma skin cancer clinic
at the Odette Cancer Center includes a radiation on-
cologist, a plastic surgeon, and a dermatopathologist.
These practitioners assess patients and jointly render a
treatment recommendation. A patient database was
started in June 2005 to record patient demographics,
tumour characteristics, and treatment-related informa-
tion. We searched the database to identify patients with
a history of CLL who were treated with radiotherapy
after local recurrence following surgical excision of aAGGRESSIVE SCC IN CLL PATIENTS
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cutaneous SCC. Patient information including age, sex,
and time since CLL diagnosis were recorded. The pa-
tients’ CLL treatment histories were recorded. Infor-
mation on treatment-related factors, including SCC
location, number of excisions, final surgical pathology,
time to recurrence from last surgery, tumour size at
the time of radiation, radiation treatment details, and
treatment outcomes were also recorded. For patients
having more than 1 recurrent SCC treated with radia-
tion, the treatment history of only the first SCC was
recorded for the purposes of this study. The total number
of SCC lesions (including local recurrences) treated with
surgery or radiotherapy were also documented.
3. RESULTS
We identified 4 patients with a history of CLL who were
treated with radiotherapy for a cutaneous SCC after lo-
cal recurrence following surgical excision from June
2005 to August 2007. Tables I and II show patient
demographics and information on the tumour and on
treatment characteristics. Mean age of the patients was
84 years, and all SCC tumours were located in the head-
and-neck region. All patients had undergone 1 or 2 sur-
gical excisions before radiation delivery, and the final
surgical pathology had shown positive margins for in-
vasive disease in 2 of the 4 patients. Time to recur-
rence was much shorter in patients with positive
margins than in those with negative margins: a mean
of 2.5 weeks as compared with 21 weeks. All patients
developed metachronous cutaneous SCC tumours
(separate lesions developing over time). Total SCC le-
sions (including local recurrences) treated with surgi-
cal excision or radiation numbered 5, 10, 11, and 4 for
patients 1, 2, 3, and 4 respectively.
Radiotherapy was delivered with curative intent
for all patients. The 2 patients who had positive mar-
gins after excision had multiple nodules, which recurred
rapidly (4 or fewer weeks) in the surgical bed. In those
patients, the SCC lesions continued to grow during the
course of radiation; the radiation treatment field had to
be enlarged to encompass the disease.
Three patients were prescribed a dose of 50 Gy in
20 fractions. One patient, case 4, was treated twice
daily (40 Gy in 20 fractions) because of rapid tumour
growth. The result was dramatic tumour regression at
1 month, and no visible evidence of disease at 2 months’
follow-up after radiation treatment (Figure 1). However,
at the time of this patient’s 2-month visit, a new 1.0-cm
SCC was detected in the region of the right temple. Be-
cause the patient was being followed in the
multidisciplinary clinic, a plastic surgeon was able to
examine the patient and excise the lesion that same day.
Table III presents patient outcomes. Two patients
achieved complete regression of disease; 2 had local
recurrence at 5 months and 11 months after treatment
completion. Longer follow-up is required for the other
2 patients to determine whether they will have a dura-
ble response to radiation.
Table IV shows CLL history in the patients, includ-
ing chemotherapy use. One patient received chemo-
therapy, including fludarabine, while receiving
treatment for SCC. This patient ultimately died from
progressive SCC.
4. DISCUSSION
The present report is the first to highlight the important
role of radiation therapy in the management of patients
with aggressive cutaneous SCC and a history of CLL.
We describe 4 patients seen in our multidisciplinary
non-melanoma skin cancer clinic who had local recur-
rence following surgical excision of a cutaneous SCC
in the head-and-neck region, where further surgery was
not recommended, and the treatment modality of choice
was local radiotherapy. Although the final outcome for
all patients was not total eradication of local disease,
TABLE I Patient characteristics and tumour characteristics for the
site treated
Case Age Sex SCC Excisions Final Time to
site before RT surgical local recurrence
(n) pathology from last surgery
(margins) (weeks)
1 92 Male Temple 1 Positive 1
2 80 Female Cheek 1 Negative 22
3 82 Female Forehead 2 Negative 20
4 79 Male Scalp 2 Positive 4
SCC = squamous-cell carcinoma; RT = radiation therapy.
TABLE II Radiation treatment details
Case                            Tumour size Radiation Treatment Field
                             at time of field size prescription enlarged
                       radiation treatment (cm) [dose (Gy)/fractions] during
treatment?
1 Numerous small nodules in surgical bed (largest, 1.0 cm) 13.0 × 14.0 50/20 Yes
2 4.0 × 3.0 cm 10.0 × 10.0 50/20 No
3 2 Nodules in surgical bed (largest, 3.5 × 1.5 cm) 10.0 × 10.0 50/20 No
4 Numerous nodules in surgical bed (largest, 3.0 × 2.0 cm) 14.0 × 21.0 40/20 Yes
(twice daily)WONG et al.
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diagnosis. The increased incidence and aggressive be-
haviour of cutaneous SCC is thought to be related to the
inherent immune defects seen with CLL (some of which
occur as a consequence of CLL therapy), together with
DNA damage from ultraviolet radiation. Ultraviolet ra-
diation generates specific mutations (thymidine dimers)
in the TP53 tumour-suppressor gene. Keratinocytes with
TP53 mutations cannot undergo apoptosis and instead
undergo clonal expansion, which manifests clinically
as actinic keratosis. Uncontrolled proliferation of ab-
normal cells leads to squamous-cell carcinoma in situ
and invasive squamous-cell carcinoma 7.
Chronic lymphocytic leukemia is characterized by
an accumulation of immunologically incompetent B
cells. These cells produce reduced amounts of nor-
mal immunoglobulins in response to antigenic stimuli.
Abnormalities of the normal B, T, and natural killer
cell functions are also seen 14. The chemotherapeutic
agents used to treat CLL also cause immunosuppres-
sion. Fludarabine in particular causes depletion of T
lymphocytes for many months, and because the T-
cell response plays a significant role in controlling
SCC, fludarabine use may cause SCC to flare or
metastasize rapidly. Previous case reports have shown
rapid development and progression of SCC after
fludarabine use 15,16. One patient in our series with
multiple SCC lesions had been on fludarabine for a month
before the rapid growth of her SCC, and she ultimately
died of progressive SCC.
(A) (B)
TABLE III  Patient outcomes
Case         Local outcome Metachronous Current
lesions? status
1 Local control at 2 months Y Alive
2 Local recurrence at 11 months Y Alive
3 Local recurrence at 5 months Y Deceased (from SCC)
4 Local control at 2 months Y Alive
TABLE IV   History and treatment of chronic lymphocytic leukemia
(CLL)
Case Time since Chemotherapy Chemotherapy
CLL diagnosis agents since used
(years) CLL diagnosis during/after RT?
1 5 No No
2 18 Chlorambucil No
3 4 Chlorambucil, fludarabine Yes (both agents used)
4 8 Chlorambucil Yes
FIGURE 1  Case 4. (A) Pre- and (B) 2-month post-treatment images, showing complete clinical response to radiation treatment.
radiation was able to provide local control for several
months.
Adami et al. 6 previously reported that patients with
CLL have a relative risk of developing cutaneous SCC
that is 8.6 times the risk seen in the general population,
with a progressive increase after the first decade of CLLAGGRESSIVE SCC IN CLL PATIENTS
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Our series agrees with other work reporting high rates
of multiple tumours, local recurrence, metastases, and
mortality from cutaneous SCC in patients with CLL 8–13.
In the series from Weimar et al. 8, all the patients de-
veloped tumour recurrence and regional metastasis
after various treatments. Perez–Reyes and Farhi 9 found
a 50% rate of regional metastasis, a 37% tumour mul-
tiplicity rate, and a 33% rate of tumour persistence or
recurrence following various treatments in patients with
CLL and SCC of the head and neck.
Ascertaining clinically whether palpable head-and-
neck nodes are the result of infiltration by CLL or SCC
is difficult, and because nodal pathology was not ob-
tained in all patients in our series, we cannot comment
on the rate of regional metastases. In fact, both types
of metastases may be present, and cancer-to-cancer
metastases of cutaneous SCC to a lymph node replaced
by CLL has been reported 17.
In our series, all patients had multiple tumours,
highlighting the aggressive behaviour of SCC in patients
with CLL. All patients responded to radiotherapy with
shrinkage and eradication of disease based on clinical
exam. However, the duration of response was limited,
because 2 patients recurred (one at 5 months, the other
at 11 months). Longer follow-up is required for the other
2 patients, to assess whether they will have a durable
response to radiation.
Radiotherapy is the recommended treatment mo-
dality for the radical primary treatment of non-
melanoma skin cancer when the anatomic, functional,
and cosmetic outcome would be better than that with
surgery, with an equivalent cure rate; when the tumour
is not amenable to complete surgical resection because
of size or location; when patient preference dictates;
or when contraindications to surgery exist. Examples
include small lesions on the lip, eyelid, or nose (which
are difficult to reconstruct surgically), and larger le-
sions on the scalp, ears, and forehead. Radiation is of-
ten used when tumours have recurred after surgery,
especially when re-excision would cause functional or
cosmetic defects or would be expected to result in posi-
tive margins, or when, in the adjuvant setting, the risk
of local recurrence is perceived to be high.
For the patients in our series, further surgery was
not recommended because of the site and extent of
recurrence. Large radiation fields were needed to en-
compass the disease and the surgical bed at risk for
microscopic disease. When metachronous lesions or
regional metastases develop in the head-and-neck re-
gion, repeat courses of radiation can be challenging,
because the treatment fields have the potential to over-
lap. Intensity-modulated radiation therapy (IMRT),
wherein radiation can be conformally delivered to the
target volume while minimizing dose to nearby nor-
mal or previously treated tissue, may be an option in
some circumstances.
When SCC lesions recur or when residual disease
remains after radical radiation, management options
are limited. Further radiation is rarely possible because
of the previous treatment having approached the toler-
ance doses of normal tissue within the treated field.
Surgery may not be possible because surgical excision
was not recommended initially, unless the recurrent
tumour was small, localized, and located in a place
where excision and reconstruction would not cause sig-
nificant morbidity. Furthermore, operating in a previ-
ously irradiated field may be suboptimal because of
radiation fibrosis and compromised vasculature. The
high rate of local relapse combined with rapid tumour
growth makes a reasonable case for exploration of the
role of hyperfractionation and dose escalation, or of
alternative treatment modalities such as high-intensity
focused ultrasound.
5. CONCLUSIONS
The management of cutaneous SCC in patients with
CLL is challenging. Patients are typically elderly, with
multiple comorbidities. Patient care is ideally managed
in a multidisciplinary setting with involvement of a
dermatologist, plastic surgeon, radiation oncologist, and
hematologist. Multiple lesions often develop over time,
and therefore regular skin surveillance is recommended.
Questionable skin lesions should be biopsied early and
should be completely excised if malignant. A low rate
of local control, rapid tumour growth, and a high rate
of metastasis are the causes of death in many of these
patients. Early detection and aggressive treatment are
vital for reducing morbidity and mortality. Recurrent
lesions can be effectively treated with local radiotherapy.
Dose escalation through IMRT or hyperfractionation to
improve local control is worthy of exploration. Systemic
therapy to reduce the risk of metachronous lesions and
regional and distant metastases should also be consid-
ered in selected patients.
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